Literature DB >> 21934298

Cytokine-induced apoptosis of beta-thalassemia/hemoglobin E erythroid progenitor cells via nitric oxide-mediated process in vitro.

Wasinee Kheansaard1, Prapaporn Panichob, Suthat Fucharoen, Dalina I Tanyong.   

Abstract

BACKGROUND/AIM: β-Thalassemia/hemoglobin E (β-thal/HbE) is a common hereditary anemia in Thailand. Ineffective erythropoiesis due to apoptosis and decreased lifespan of circulating thalassemic red blood cells are the major causes of anemia. Changes to bone marrow microenvironment could contribute to apoptotic events. This study examined the effects of cytokines interleukin-1β, tumor necrosis factor-α and interferon-γ on apoptosis of β-thal/HbE erythroid progenitor cells in vitro, including nitric oxide-mediated apoptotic processes.
METHODS: Percent apoptosis of erythroid progenitor cells from 5 β-thal/HbE patients and 5 normal control subjects was examined using flow cytometry. In addition, the inducible nitric oxide synthase (iNOS) mRNA level and nitrite production were measured using quantitative PCR and the Griess method, respectively.
RESULTS: Upon cytokine treatment, a higher percent apoptosis was obtained with β-thal/HbE erythroid progenitor cells compared with control, and the maximum effect was observed using 20 ng/ml interferon-γ on day 14 of culture. There was an increase in iNOS mRNA level and a concomitant elevation of nitrite concentration in culture medium. Apoptosis and nitrite level were abrogated when β-thal/HbE and control cells were treated with S-methylisothiourea sulfate, an iNOS inhibitor.
CONCLUSION: The marked sensitivity of erythroid progenitor cells from β-thal/HbE patients to cytokine-induced apoptosis via an NO-mediated process reflects a proapoptotic status of such thalassemic red blood cells.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21934298     DOI: 10.1159/000329903

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  6 in total

Review 1.  HbE/β-Thalassemia and Oxidative Stress: The Key to Pathophysiological Mechanisms and Novel Therapeutics.

Authors:  Rhoda Elison Hirsch; Nathawut Sibmooh; Suthat Fucharoen; Joel M Friedman
Journal:  Antioxid Redox Signal       Date:  2016-11-28       Impact factor: 8.401

2.  Effect of Tumor Necrosis Factor-Alpha on Erythropoietin and Erythropoietin Receptor-Induced Erythroid Progenitor Cell Proliferation in β-Thalassemia/Hemoglobin E Patients.

Authors:  Dalina I Tanyong; Prapaporn Panichob; Wasinee Kheansaard; Suthat Fucharoen
Journal:  Turk J Haematol       Date:  2015-08-06       Impact factor: 1.831

3.  Chronic inflammation triggered by the NLRP3 inflammasome in myeloid cells promotes growth plate dysplasia by mesenchymal cells.

Authors:  Chun Wang; Can-Xin Xu; Yael Alippe; Chao Qu; Jianqiu Xiao; Ernestina Schipani; Roberto Civitelli; Yousef Abu-Amer; Gabriel Mbalaviele
Journal:  Sci Rep       Date:  2017-07-07       Impact factor: 4.379

4.  Decreased nitrite reductase activity of deoxyhemoglobin correlates with platelet activation in hemoglobin E/ß-thalassemia subjects.

Authors:  Attaphon Chamchoi; Sirada Srihirun; Kittiphong Paiboonsukwong; Thanaporn Sriwantana; Piyadon Sathavorasmith; Kovit Pattanapanyasat; Rhoda Elison Hirsch; Alan N Schechter; Nathawut Sibmooh
Journal:  PLoS One       Date:  2018-09-20       Impact factor: 3.240

Review 5.  Role of Extrinsic Apoptotic Signaling Pathway during Definitive Erythropoiesis in Normal Patients and in Patients with β-Thalassemia.

Authors:  Olga Raducka-Jaszul; Dżamila M Bogusławska; Natalia Jędruchniewicz; Aleksander F Sikorski
Journal:  Int J Mol Sci       Date:  2020-05-08       Impact factor: 5.923

6.  Gasdermin D mediates the pathogenesis of neonatal-onset multisystem inflammatory disease in mice.

Authors:  Jianqiu Xiao; Chun Wang; Juo-Chin Yao; Yael Alippe; Canxin Xu; Dustin Kress; Roberto Civitelli; Yousef Abu-Amer; Thirumala-Devi Kanneganti; Daniel C Link; Gabriel Mbalaviele
Journal:  PLoS Biol       Date:  2018-11-02       Impact factor: 8.029

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.